AI-generated summary
The authors report a non-randomized prospective clinical trial of 53 women with breast cancer receiving radiotherapy, comparing blue LED (470 nm) photobiomodulation before each session with a control group. They found radiodermatitis occurred 28% less often in the intervention group, and quality of life worsened over time only in the control group. The study was non-randomized, so the authors' suggestion that blue LED may be promising should be read cautiously.
- Participants
- 53
- Who or what was studied
- Women diagnosed with breast cancer undergoing radiotherapy, divided into an intervention group (n = 26) and a control group (n = 27)
- Wavelengths
- 470 nm
- Limits stated in the abstract
- The trial was non-randomized, which the abstract notes as a design feature without describing its implications for bias.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 470 nm
- Energy density (fluence)
- 18.6 J/cm2
- Total energy
- 108 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode, Photobiomodulation, Control group, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.